According to the company’s latest financial disclosure, revenue rose to ¥103.00 million, up from ¥83.00 million in the prior year. This growth helped mitigate operational costs, leading to a narrowed operating loss of ¥573.00 million compared to ¥630.00 million a year ago. The company’s pretax loss also saw a contraction, finishing the nine-month period at ¥509.00 million.

Shareholder Returns and EPS Data

On a per-share basis, the net loss improved to ¥37.14, down from the ¥49.20 loss reported in the previous fiscal period. Despite the narrowing losses, the company confirmed it will not issue a dividend for the current fiscal year, maintaining a payout of ¥0.00 across all quarters.

Key highlights from the nine-month report include:

• A 24% increase in total revenue year-over-year.
• A reduction in net loss by approximately ¥147 million.
• Adherence to Japanese accounting standards for all reported figures.

Perseus Proteomics continues to focus on its core research and development pipeline, opting to reinvest capital rather than issue dividends. The firm’s stock, traded under the ticker 4882.TO, reflects the ongoing challenges of the capital-intensive biotechnology sector in Japan.